NewYork-Presbyterian
Weill Cornell Medical Center

Outreach Services
July 2022

Memo update- Thrombophilia Risk test back in-house

Who is this message for:
New York Presbyterian Hospital/Weill Cornell Medicine healthcare providers and clients

What is happening:
Effective immediately, Thrombophilia Risk Test for *Factor V Leiden* and *Factor II Prothrombin mutations* will be routed back to in-house testing using a new platform.

The corresponding tests provided by ARUP are listed below:

EPIC PROCEDURE (ORDERABLE)	Cerner Orderable	EPIC CODE	Emdeon Code
FACTOR V LEIDEN	FV Leiden	LAB6340	21813569
PROTHROMBIN (FACTOR II) MUTATION	FactorII	LAB6103	21811728
Methylenetetrahydrofolate Reductase (MTHFR)	MTHFR Mutation Detection PCR	LAB6170	4262492

What you will need to do:
We will now require collection of 5 mL of peripheral blood (minimum 1 mL) into each of two lavender (EDTA) top tubes, the first for Factor II Prothrombin and Factor V Leiden mutation. Kindly be advised, testing for MTHFR Mutations (Methylenetrahydrofolate Reductase) will still be *permanately* performed at ARUP Laboratories.

Why we are making this change:
The manufacturer has discontinued production of reagents used for this test. We have completed the validation of a new in-house test *for Factor II Prothrombin Mutation* and *Factor V Leiden Mutation* that will now be performed on the Cepheid platform.

For any questions, please contact:
Hanna Rennert, Director, Molecular Pathology
har2006@med.cornell.edu, 212-746-6412

Liliana Serrano, Supervisor, Molecular Pathology
lis9134@nyp.org, 212-746-2294

Outreach Client Services Department
212-746-0670